- Doximity, Inc. recently reported past fourth-quarter and full-year fiscal 2026 results, with revenue rising to US$145.37 million for the quarter and US$644.86 million for the year, but net income and earnings per share declining versus the prior year as profitability came under pressure.
- At the same time, Doximity announced a new integration that brings its Clinical AI Suite, including Scribe and Ask, into Aledade’s value-based care platform, underscoring how its AI tools are being embedded directly into physicians’ everyday workflows.
- We’ll now examine how softer fiscal 2027 guidance, driven partly by higher AI-related spending, reshapes Doximity’s previously optimistic investment narrative.
Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
Doximity Investment Narrative Recap
To own Doximity, you need to believe its physician network and AI workflow tools can stay central to how U.S. clinicians work, even as growth slows and pharma ad budgets wobble. The key short term catalyst is whether heavier AI spending begins to translate into clearer revenue opportunities, while the biggest current risk is margin pressure from that same AI investment combined with softer pharma marketing demand. The latest results and fiscal 2027 guidance materially sharpen both of those concerns.
Against that backdrop, the new Aledade integration looks especially important. Embedding Scribe and Ask directly into Aledade Assist’s value based care platform reinforces Doximity’s role inside everyday clinical workflows, which matters if investors are watching for evidence that AI tools can deepen stickiness with health systems and prescribers, even while near term profitability and growth guidance disappoint.
But beneath the appeal of AI tools and workflow integrations, investors should also be aware that ...
Read the full narrative on Doximity (it's free!)
Doximity's narrative projects $782.1 million revenue and $249.4 million earnings by 2029.
Uncover how Doximity's forecasts yield a $37.77 fair value, a 99% upside to its current price.
Exploring Other Perspectives
Some of the lowest estimate analysts were already cautious, assuming only about 7 percent annual revenue growth to roughly US$784 million and shrinking margins, and this latest guidance plus AI spending debate could either validate that view or prompt a rethink, so it is worth comparing these more pessimistic expectations with your own assumptions before deciding how you feel about Doximity’s next chapter.
Explore 5 other fair value estimates on Doximity - why the stock might be worth just $25.00!
The Verdict Is Yours
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Doximity research is our analysis highlighting 2 key rewards that could impact your investment decision.
- Our free Doximity research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Doximity's overall financial health at a glance.
Looking For Alternative Opportunities?
Every day counts. These free picks are already gaining attention. See them before the crowd does:
- AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
- We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com